Replimune Group (NASDAQ:REPL) Rating Increased to Neutral at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of Replimune Group (NASDAQ:REPL) from an underweight rating to a neutral rating in a report issued on Friday, Marketbeat Ratings reports. The firm currently has $8.00 price objective on the stock.

Other research analysts have also recently issued research reports about the company. BMO Capital Markets cut Replimune Group from a “market perform” rating to an “underperform” rating in a research report on Monday, April 13th. Cantor Fitzgerald cut Replimune Group from an “overweight” rating to a “hold” rating in a research report on Monday, April 13th. Weiss Ratings raised Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 8th. Piper Sandler cut Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price objective on the stock. in a research report on Friday, April 10th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $2.00 price objective (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. Seven analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $4.38.

Replimune Group Trading Up 85.7%

Shares of Replimune Group stock opened at $8.69 on Friday. The stock has a fifty day simple moving average of $4.88 and a 200 day simple moving average of $7.26. Replimune Group has a 12-month low of $1.50 and a 12-month high of $13.24. The company has a market capitalization of $717.56 million, a P/E ratio of -2.53 and a beta of 0.12. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33.

Insider Activity

In related news, insider Christopher Sarchi sold 6,500 shares of the business’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total transaction of $52,065.00. Following the sale, the insider directly owned 151,588 shares in the company, valued at approximately $1,214,219.88. The trade was a 4.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Institutional investors have recently added to or reduced their stakes in the business. ProShare Advisors LLC boosted its holdings in Replimune Group by 10.3% during the 4th quarter. ProShare Advisors LLC now owns 16,116 shares of the company’s stock valued at $157,000 after acquiring an additional 1,505 shares during the period. JPMorgan Chase & Co. boosted its holdings in Replimune Group by 4.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock valued at $159,000 after acquiring an additional 1,712 shares during the period. Ballentine Partners LLC boosted its holdings in Replimune Group by 7.8% during the 4th quarter. Ballentine Partners LLC now owns 23,665 shares of the company’s stock valued at $230,000 after acquiring an additional 1,721 shares during the period. BNP Paribas Financial Markets boosted its holdings in Replimune Group by 37.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after acquiring an additional 1,879 shares during the period. Finally, NEOS Investment Management LLC boosted its holdings in Replimune Group by 5.0% during the 3rd quarter. NEOS Investment Management LLC now owns 42,966 shares of the company’s stock valued at $180,000 after acquiring an additional 2,060 shares during the period. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.